Skip to main content
    R

    Rhythm Pharmaceuticals Inc (RYTM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $116.61
    +9.13 (+8.49%)

    Market Cap: $7.97B

    Last updated: Nov 17, 2026 at 4:35 PM ET

    Rhythm Pharmaceuticals Inc (RYTM) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Rhythm Pharmaceuticals (RYTM) has a market cap of $7.97B and an enterprise value of $8.04B. It kept -69.03% of revenue as net income over the last 12 months. Revenue grew 61.04% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 0.79% above the market cap, as debt exceeds cash.

    Market Cap$7.97B
    Enterprise Value$8.04B
    Latest price (Nov 17, 2026)$116.61

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 3, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.66% in the quarter ended Sep 30, 2026 and grew 6.20% a year over 2 years.

    Shares Outstanding69.05M
    Shares Change (YoY)+4.20%
    Shares Change (QoQ)+0.66%
    Share Count Growth (2Y CAGR)+6.20%

    Valuation Ratios

    Sales and book value multiples are 28.7x and 91.5x. Its year-end P/S ranged from 26.3x to 158.9x from 2021 to 2025.

    P/S Ratio28.7x
    Forward P/S24.1x
    P/B Ratio91.5x
    P/TBV Ratio112.9x

    Valuation history and multiples

    Price Statistics

    The stock is up 17.30% over 52 weeks and trades 19.88% above its 50-day average.

    Beta (1Y)1.20
    52-Week Change+17.30%
    1-Month Change+32.17%
    3-Month Change+0.76%
    6-Month Change+33.71%
    5-Year Change+704.26%
    Total Return (1Y)+17.30%
    Total Return (3Y CAGR)+51.06%
    Total Return (5Y CAGR)+59.15%
    Return vs SPY (1Y)+4.46%
    Max Drawdown (1Y)-35.54%
    Max Drawdown (3Y)-35.54%
    Sharpe Ratio (1Y)0.28
    Correlation with SPY (1Y)0.31
    50-Day Average$97.27
    200-Day Average$97.31
    52-Week Range$74.50 to $122.20
    RSI (14 Days)63.5
    Average Volume (20 Days)1.91M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.78x current liabilities, and total debt is 1.17x shareholder equity.

    Current Ratio2.78x
    Quick Ratio2.57x
    Debt / Equity1.17x
    Interest Coverage-10.31x

    Returns and Efficiency

    Return on invested capital is -98.64% and return on equity is -220.32% over the last 12 months.

    Return on Equity (ROE)-220.32%
    Return on Assets (ROA)-43.74%
    Return on Invested Capital (ROIC)-98.64%
    Return on Capital Employed (ROCE)-64.34%
    ROA (5Y Average)-46.27%
    Asset Turnover0.59x
    Inventory Turnover1.07x
    Receivables Turnover7.06x
    Cash Conversion Cycle244 days

    Scores

    RYTM has an Altman Z-Score of 15.22, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score15.22
    Altman Z ZoneSafe
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $280.75M over the last 12 months.

    Revenue$280.75M
    Revenue Growth (YoY)+61.04%
    Gross Profit$247.69M
    Operating Income-$187.25M
    Pretax Income-$192.24M
    Net Income-$193.81M
    EBIT-$188.03M
    Reported EPS (TTM)-$2.90

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 19.85% of the $443.13M in total assets.

    Cash and Equivalents$39.98M
    Total Debt$102.67M
    Net Debt$62.69M
    Net Debt Per Share$0.91
    Working Capital$268.47M
    Shareholder Equity$87.97M
    Book Value Per Share$1.27
    Tangible Book Value$71.29M
    Tangible Book Per Share$1.03
    Total Assets$443.13M
    Total Liabilities$241.59M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$81.79M
    FCF Per Share-$1.20
    Depreciation and Amortization$6.47M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -66.70%.

    Gross Margin88.23%
    Operating Margin-66.70%
    Pretax Margin-68.48%
    Net Margin-69.03%
    EBIT Margin-66.98%
    Gross Margin (5Y Average)87.89%

    Growth

    Revenue grew 100.23% a year over 3 years.

    Revenue Growth (3Y CAGR)+100.23%
    Book Value Per Share Growth (2Y CAGR)-14.83%
    Tangible Book Per Share Growth (2Y CAGR)-14.69%

    Revenue and profit by year

    Dividends and Yields

    RYTM does not pay a dividend.

    Buyback Yield-0.03%
    Shareholder Yield-0.03%

    Peer Position

    Against 9 similar companies, RYTM has the 3rd highest P/S.

    P/S Ratio28.7x vs 11.1x median
    ROIC-98.64% vs -12.75% median
    Revenue Growth (Trailing 4 Quarters, YoY)+61.04% vs +29.53% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 74.56% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+74.56%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About RYTM

    What is RYTM's market cap?

    Rhythm Pharmaceuticals has a market cap of $7.97B. Its enterprise value, which adds debt and subtracts cash, is $8.04B.

    How many shares of RYTM are outstanding?

    Rhythm Pharmaceuticals has 69.05M shares outstanding. The count is up 4.20% from a year earlier.

    Does RYTM pay a dividend?

    No. Rhythm Pharmaceuticals does not pay a dividend.

    How much debt does RYTM have?

    Rhythm Pharmaceuticals has $102.67M of total debt and $39.98M of cash and equivalents, a net debt position of $62.69M.